<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>r10q012.txt
<TEXT>

                   SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C.  20549

                               Form 10-Q

   X   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
       SECURITIES EXCHANGE ACT OF 1934

   For the quarterly period ended June 30, 2001.

                                   OR

   __  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
       SECURITIES EXCHANGE ACT OF 1934

   For the transition period from _______________to __________________.

                     Commission file number 1-7928

                       BIO-RAD LABORATORIES, INC.
         (Exact name of registrant as specified in its charter)

             Delaware                        94-1381833
   (State or other jurisdiction           (I.R.S. Employer
    of incorporation or organization)      Identification No.)


       1000 Alfred Nobel Drive, Hercules, California 94547
   (Address of principal executive offices)      (Zip Code)

   Registrant's telephone number, including area code
                    (510) 724-7000

                               No Change
   Former name, former address and former fiscal year, if changed since last
   report.

   Indicate by check whether the registrant (1) has filed all reports required
   to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
   during the preceding 12 month (or for such shorter period that the
   registrant was required to file such reports), and (2) has been subject
   to such  filing requirements for the past 90 days.  Yes    X    No  _____

   Indicate the number of shares outstanding of each of the issuer's classes
   of commonstock ,as of the latest practicable date--
                                                            SharesOutstanding
                   Title of each Class                      at July 31, 2001

                   Class A Common Stock,
                    Par Value $1.00 per share                   10,067,218

                   Class B Common Stock,
                    Par Value $1.00 per share                    2,426,328


 <page>



                                   BIO-RAD LABORATORIES, INC.

                            Condensed Consolidated Statements of Income
                              (In thousands, except per share data)
                                           (Unaudited)
  <table>
  <caption>
                                                   Three Months Ended    Six Months Ended
                                                         June 30,             June 30,
                                                     2001      2000       2001      2000
   <s>                                            <c>        <c>        <c>       <c>
   NET SALES . . . . . . . . . . . . . . . . . .  $195,354   $186,826   $398,022  $372,289

   Cost of goods sold  . . . . . . . . . . . . .    85,612     87,193    176,930   173,913

   GROSS PROFIT  . . . . . . . . . . . . . . . .   109,742     99,633    221,092   198,376

   Selling, general and administrative expense .    65,341     64,004    127,940   126,499

   Product research and development expense  . .    17,701     17,380     36,129    35,251

   INCOME FROM OPERATIONS  . . . . . . . . . . .    26,700     18,249     57,023    36,626

   Interest expense  . . . . . . . . . . . . . .    (5,940)    (7,802)   (12,529)  (16,568)

   Other, net  . . . . . . . . . . . . . . . . .    (2,410)    (2,985)   (12,542)   (8,250)

   INCOME BEFORE TAXES . . . . . . . . . . . . .    18,350      7,462     31,952    11,808

   Provision for income taxes  . . . . . . . . .     6,789      2,388     11,822     3,779

   NET INCOME  . . . . . . . . . . . . . . . . .  $ 11,561   $  5,074   $ 20,130  $  8,029
                                                  ========   ========   ========  ========


   Basic earnings per share:
      Net income . . . . . . . . . . . . . . . .     $0.94      $0.42      $1.64     $0.66
                                                  ========   ========   ========  ========
      Weighted average common shares . . . . . .    12,299     12,218     12,277    12,198
                                                  ========   ========   ========  ========
   Diluted earnings per share:
      Net income . . . . . . . . . . . . . . . .     $0.91      $0.41      $1.59     $0.65
                                                  ========   ========   ========  ========
      Weighted average common shares . . . . . .    12,681     12,270     12,621    12,261
                                                  ========   ========   ========  ========


   The accompanying notes are an integral part of these statements.
   </table>





                                                   1
   <page>



                               BIO-RAD LABORATORIES, INC.
                          Condensed Consolidated Balance Sheets
                            (In thousands, except share data)
                                     (Unaudited)
  <table>
  <caption>
                                                                  June 30,    December 31,
                                                                    2001           2000
    <s>
    ASSETS:                                                       <c>            <c>
    Cash and cash equivalents  . . . . . . . . . . . . . . .      $ 26,066       $ 13,954

    Accounts receivable  . . . . . . . . . . . . . . . . . .       186,708        182,242
    Inventories  . . . . . . . . . . . . . . . . . . . . . .       142,285        132,519

    Prepaid expenses, taxes and other current assets . . . .        40,407         40,953
       Total current assets  . . . . . . . . . . . . . . . .       395,466        369,668

    Net property, plant and equipment  . . . . . . . . . . .       128,982        119,032
    Goodwill, net  . . . . . . . . . . . . . . . . . . . . .        84,625         90,970

    Other assets . . . . . . . . . . . . . . . . . . . . . .        51,579         66,608
         Total assets. . . . . . . . . . . . . . . . . . . .      $660,652       $646,278
                                                                  ========       ========
    LIABILITIES AND STOCKHOLDERS' EQUITY:

    Accounts payable . . . . . . . . . . . . . . . . . . . .      $ 60,615       $ 62,965
    Accrued payroll and employee benefits  . . . . . . . . .        46,151         52,354

    Notes payable and current maturities of long-term debt .        17,334         18,146
    Sales, income and other taxes payable  . . . . . . . . .        17,812          8,413

    Other current liabilities  . . . . . . . . . . . . . . .        59,302         47,430
       Total current liabilities . . . . . . . . . . . . . .       201,214        189,308

    Long-term debt, net of current maturities  . . . . . . .       194,715        203,360
    Deferred tax liabilities . . . . . . . . . . . . . . . .         8,389          8,992

       Total liabilities . . . . . . . . . . . . . . . . . .       404,318        401,660
    STOCKHOLDERS' EQUITY:

    Preferred stock, $1.00 par value, 2,300,000 shares
      authorized; none outstanding . . . . . . . . . . . . .            --             --
    Class A common stock, $1.00 par value, 15,000,000 shares
      authorized; outstanding - 10,064,718 at June 30, 2001
      and 10,042,200 at December 31, 2000. . . . . . . . . .        10,065         10,042

    Class B common stock, $1.00 par value, 6,000,000 shares
      authorized; outstanding - 2,426,328 at June 30, 2001
      and 2,435,928 at December 31, 2000 . . . . . . . . . .         2,426          2,436
    Additional paid-in capital . . . . . . . . . . . . . . .        19,468         19,120

    Class A treasury stock, 161,649 shares at June 30, 2001
      and 244,499 shares at December 31, 2000 at cost  . . .        (3,580)        (5,415)
    Retained earnings  . . . . . . . . . . . . . . . . . . .       252,134        231,821

    Accumulated other comprehensive income:
      Currency translation and other . . . . . . . . . . . .       (24,179)       (13,386)

      Total stockholders' equity.  . . . . . . . . . . . . .       256,334        244,618
         Total liabilities and stockholders' equity. . . . .      $660,652       $646,278
                                                                  ========       ========



  The accompanying notes are an integral part of these statements.
  </table>


                                                 2
  <page>





                                   BIO-RAD LABORATORIES, INC.
                         Condensed Consolidated Statements of Cash Flows
                                         (In thousands)
                                           (Unaudited)
<table>
<caption>
                                                                          Six Months Ended
                                                                              June 30,
                                                                          2001         2000
   <s>                                                                  <c>         <c>
   Cash flows from operating activities:
        Cash received from customers . . . . . . . . . . . . . . .      $380,038    $365,227
        Cash paid to suppliers and employees . . . . . . . . . . .      (333,934)   (333,482)
        Interest paid. . . . . . . . . . . . . . . . . . . . . . .       (11,594)    (11,890)
        Income tax payments  . . . . . . . . . . . . . . . . . . .        (2,699)     (5,317)
        Miscellaneous receipts (payments). . . . . . . . . . . . .         5,188      (2,573)
        Net cash provided by operating activities. . . . . . . . .        36,999      11,965

   Cash flows from investing activities:
        Capital expenditures, net. . . . . . . . . . . . . . . . .       (19,651)    (17,057)
        Net sales of marketable securities and investments . . . .            92         204
        Foreign currency hedges, net . . . . . . . . . . . . . . .         1,183       3,461
        Net cash used in investing activities. . . . . . . . . . .       (18,376)    (13,392)

   Cash flows from financing activities:
        Net payments under line-of-credit arrangements . . . . . .        (1,528)     (2,143)
        Long-term borrowings . . . . . . . . . . . . . . . . . . .        74,250     347,498
        Payments on long-term debt . . . . . . . . . . . . . . . .       (81,899)   (343,543)
        Arrangement and other fees for long-term financing . . . .            --      (4,500)
        Proceeds from issuance of common stock . . . . . . . . . .           361         289
        Treasury stock activity, net . . . . . . . . . . . . . . .         2,018       1,469

        Net cash used in financing activities. . . . . . . . . . .        (6,798)       (930)

   Effect of exchange rate changes on cash . . . . . . . . . . . .           287      (1,659)

   Net increase (decrease) in cash and cash equivalents  . . . . .        12,112      (4,016)
   Cash and cash equivalents at beginning of period. . . . . . . .        13,954      17,087

   Cash and cash equivalents at end of period. . . . . . . . . . .      $ 26,066    $ 13,071
                                                                        ========    ========
   Reconciliation of net income to net cash provided
     by operating activities:
      Net income . . . . . . . . . . . . . . . . . . . . . . . . .      $ 20,130    $  8,029
      Adjustments to reconcile net income to net cash
        provided by operating activities:
          Depreciation and amortization  . . . . . . . . . . . . .        20,246      21,726
          Foreign currency hedge transactions, net . . . . . . . .        (1,183)     (3,461)
          Gains on disposition of marketable securities. . . . . .           (81)       (392)
          (Increase) decrease in accounts receivable . . . . . . .       (13,982)        504
          Increase in inventories  . . . . . . . . . . . . . . . .       (13,761)    (15,004)
          (Increase) decrease in other current assets. . . . . . .          (608)      3,186
          Increase (decrease) in accounts payable
            and all other current liabilities. . . . . . . . . . .         6,460      (6,376)
          Increase (decrease) in income taxes payable  . . . . . .         9,562        (971)
          Other. . . . . . . . . . . . . . . . . . . . . . . . . .        10,216       4,724

   Net cash provided by operating activities . . . . . . . . . . .      $ 36,999    $ 11,965
                                                                        ========    ========
   Non-cash investing and financing activities:
     Liabilities assumed in building purchase. . . . . . . . . . .      $  3,777    $     --
                                                                        ========    ========

  The accompanying notes are an integral part of these statements.
 </table>



                                                 3
  <page>

                      BIO-RAD LABORATORIES, INC.

         Notes to Condensed Consolidated Financial Statements
                             (Unaudited)

  1. BASIS OF PRESENTATION

  The accompanying unaudited condensed consolidated financial
  statements of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the
  "Company"), reflect all adjustments which are, in the opinion of
  management, necessary to a fair statement of the results of the
  interim periods presented.  All such adjustments are of a normal
  recurring nature.  The condensed consolidated financial
  statements should be read in conjunction with the notes to the
  consolidated financial statements contained in the Company's
  Annual Report for the year ended December 31, 2000.  Certain
  amounts in the financial statements of the prior year have been
  reclassified to be consistent with the 2001 presentation.

  2. INVENTORIES

  The principal components of inventories are as follows (in
  thousands):

                                          June 30,    December 31,
                                            2001          2000

  Raw materials                          $ 39,185       $ 32,993
  Work in process                          28,359         30,071
  Finished goods                           74,741         69,455
                                         --------       --------
                                         $142,285       $132,519
                                         ========       ========

  3. PROPERTY, PLANT AND EQUIPMENT

  The principal components of property, plant and equipment are as
  follows (in thousands):

                                         June 30,      December 31,
                                           2001           2000

  Land and improvements                  $ 11,065       $  8,337
  Buildings and leasehold
    improvements                           72,700         66,039
  Equipment                               176,907        180,827
                                          260,672        255,203
  Accumulated depreciation               (131,690)      (136,171)
                                          -------        -------
  Net property, plant and equipment      $128,982       $119,032
                                         ========       ========

  4.   ACQUISITIONS AND DISPOSITIONS

  In July 2000, Accent Semiconductor Technology, Inc. ("ASTI")
  acquired the assets and certain liabilities of the Company's
  semiconductor and optoelectronic metrology business.  The
  proceeds of approximately $36.0 million represent $27.0 million
  in cash, an $8.0 million note receivable due in five years and an

                                  4

  <page>

  18% equity interest in ASTI.  The Company used $17.0 million of
  the cash proceeds to reduce borrowings on the term loan portion
  of the Senior Credit facility.  The equity interest in ASTI will
  be held as a long-term investment on the cost method.

  In October 1999, the Company acquired Pasteur Sanofi Diagnostics
  S.A., a French corporation, from its shareholders, Sanofi-
  Synthelabo S.A. and Institut Pasteur.  Purchase liabilities
  recorded included approximately $14.0 million for severance and
  other employee costs and $4.0 million for the consolidation and
  closure of certain leased facilities.  The closure of facilities
  identified by the Company were completed in fiscal 2000, with
  lease payments net of sublease revenues continuing until all
  contractual obligations are met.  As of June 30, 2001, expenses
  charged against these reserves were approximately $12.9 million
  for severance and other employee costs and $2.0 million for
  facilities and asset related write-offs.

  5.   EARNINGS PER SHARE

  Weighted average shares used for diluted earnings per share
  include the dilutive effect of outstanding stock options of
  382,000 and 52,000 shares for the three month periods ended
  June 30, 2001 and 2000, respectively.

  Weighted average shares used for diluted earnings per share
  include the dilutive effect of outstanding stock options of
  344,000 and 63,000 shares, for the year-to-date periods ended
  June 30, 2001, and 2000, respectively.

  There were no anti-dilutive shares for the three month period
  ended June 30, 200l.  Options to purchase 241,000 shares of
  common stock were outstanding during the three month period ended
  June 30, 2000, but were excluded from the computation of diluted
  earnings per share because the exercise price of the options was
  greater than the average market price of the common shares.

  There were no anti-dilutive shares for the six month period ended
  June 30, 2001.  Options to purchase 209,000 shares of common
  stock were outstanding for the year-to-date period ended June 30,
  2000, but were excluded from the computation of diluted earnings
  per share because the exercise price of the options was greater
  than the average market price of the common shares.

  6.   OTHER INCOME AND EXPENSE

  The components of Other, net were (in thousands):

  <table>
                                      Three Months Ended         Six Months Ended
                                             June 30,                  June 30,
                                          2001        2000        2001       2000
                                          ----        ----        ----       ----

    <s>                                   <c>        <c>         <c>         <c>
    Goodwill amortization                $(2,021)  $(2,021)     $(4,042)    $(4,011)
    Non-operating litigation costs, net      (67)   (1,139)        (767)     (1,681)
    Write-down of investment in
      affiliates                              --         --       (2,000)        --
    Write-down of spectroscopy
      instrument product line                 --         --       (4,500)        --
    Other                                   (322)       175       (1,233)    (2,558)
                                          ------      -----       ------     ------
    Total other, net                     $(2,410)   $(2,985)    $(12,542)   $(8,250)
                                         =======     =======     =======    =======

  </table>
                                              5

  <page>


  In the first quarter of 2001, the Company recorded a $4.5 million non-
  cash pre-tax charge reflecting the potential impact of a non-binding
  letter of intent to sell the spectroscopy instrument business to a new
  owner.  Additionally, the Company recorded a $2.0 million non-cash
  pre-tax charge to adjust the value of an investment based on on-going
  discussions with the investee's management concerning its future
  capital structure.


  7.   COMPREHENSIVE INCOME

  The components of the Company's total comprehensive income were (in
  thousands):



                                    Three Months Ended        Six Months Ended
                                          June 30,                 June 30,
                                      2001        2000        2001       2000
                                      ----        ----        ----       ----

    Net Income                       $11,561    $ 5,074    $ 20,130    $ 8,029

    Currency translation adjustments  (3,965)    (1,978)    (10,686)    (7,790)
    Net unrealized holding
     gains (losses) on securities        (42)        35         (39)       498
    Reclassification adjustments for
     gains included in net income        (11)       (50)        (68)      (267)
                                     -------   --------     -------    -------
    Total comprehensive income       $ 7,543    $ 3,081     $ 9,337    $   470
                                     =======    =======     =======    =======



  8.   SEGMENT INFORMATION

  Information regarding industry segments for the three months ended
  June 30, 2001 and 2000 is as follows (in thousands):

                                Life       Clinical     Analytical
                               Science    Diagnostics   Instruments

  Segment net sales     2001    $88,342    $102,286      $ 5,368
                        2000    $62,891    $106,982      $17,836


  Segment profit(loss)  2001    $15,898     $10,900      $(1,688)
                        2000    $ 1,430     $ 9,744      $  (261)

  Information regarding industry segments for the six months ended
  June 30, 2001 and 2000 is as follows (in thousands):


                                Life       Clinical     Analytical
                               Science    Diagnostics  Instruments

  Segment net sales     2001   $181,280     $205,275     $12,873
                        2000   $130,622     $207,443     $36,215


  Segment profit(loss)  2001    $34,989      $19,022     $(2,616)
                        2000    $ 8,563      $12,736     $    80

  Inter-segment sales are primarily between Life Science and Clinical
  Diagnostics and are priced to give Life Science a representative

                                     6

  <page>

  gross margin.  Interest expense is charged to segments based on the
  carrying amount of inventory and receivables employed by that
  segment.  The following reconciles total segment profit to
  consolidated income before taxes (in thousands):



                                        Three Months Ended    Six Months Ended
                                              June 30,            June 30,
                                          2001      2000      2001       2000
                                          ----      ----      ----       ----


    Total segment profit                $25,110   $10,913     $51,395  $21,379

    Gross profit on inter-segment sales    (325)     (440)       (709)  (1,001)
    Net corporate operating, interest
     and other expense not allocated
     to segments                         (4,456)   (1,185)    (14,758)  (5,042)
    Goodwill amortization                (2,021)   (2,021)     (4,042)  (4,011)
    Investment income, net                   42       195          66      483

                                        -------   -------     -------  -------
    Consolidated income before taxes    $18,350   $ 7,462     $31,952  $11,808
                                        =======   =======     =======  =======




















                                              7
   <page>






   Item 2.   Management's  Discussion and Analysis of
             Results of Operations and Financial Condition.

   This discussion should be read in conjunction with the information
   contained both in this report and in the Company's Consolidated
   Financial Statements for the year ended December 31, 2000.

   The following table shows operating income and expense items as a
   percentage of net sales:

   <table>

                               Three Months Ended    Six Months Ended   Year Ended
                                     June 30,            June 30,      December 31,
                                2001         2000     2001       2000      2000
                                ----         ----     ----       ----      ----
     <s>                       <c>          <c>      <c>        <c>        <c>
     Net sales                 100.0%       100.0%   100.0%     100.0%     100.0%
      Cost of goods sold        43.8         46.7     44.5       46.7       47.3
     Gross profit               56.2         53.3     55.5       53.3       52.7

     Selling, general and
      administrative            33.4         34.2     32.1       34.0       34.1

     Product research and
      development                9.1          9.3      9.1        9.5        9.4

                               -----        -----    -----      -----      -----
     Income from operations     13.7%         9.8%    14.3%       9.8%       9.2%
                               =====        =====    =====      =====      =====

     Net income                  5.9%         2.7%     5.1%       2.2%       4.3%
                               =====        =====    =====      =====      =====

   </table>

   Forward Looking Statements

   Other than statements of historical fact, statements made in this
   report include forward looking statements, such as statements
   with respect to the Company's future financial performance,
   operating results, plans and objectives.  We have based these
   forward looking statements on our current expectations and
   projections about future events.  However, actual results may
   differ materially from those currently anticipated depending on a
   variety of risk factors including among other things: our ability
   to successfully develop and market new products; our reliance on
   and access to necessary intellectual property; our substantial
   leverage and ability to service our debt; competition in and
   government regulation of the industries in which we operate; and
   the monetary policies of various countries.  We undertake no
   obligation to publicly update or revise any forward looking
   statements, whether as a result of new information, future
   events, or otherwise.

                   Three Months Ended June 30, 2001
              Compared to Three Months Ended June 30, 2000

   Corporate Results - Sales, Margins and Expenses

   Net sales (sales) for the second quarter of 2001 were $195.4
   million compared to $186.8 million in the second quarter of 2000,
   an increase of 4.6%.  Sales increased 45.3% in Life Science on a
   constant currency basis for the quarter.  Clinical Diagnostics
   sales growth, adjusted for a product line divestiture on a
   constant currency basis, rose 5.8%.  The growth in Life Science
   is attributed to strong demand for the Company's proteomic and

                                   8
   <page>





   genomic products.  Sales of the Bovine Spongiform Encephalopathy
   (BSE) test (used to detect the presence of prions linked to Mad
   Cow disease) were significant as the product had negligible sales
   in the prior year.  Clinical Diagnostics growth was primarily the
   result of increases from the Company's quality control and blood
   virus product lines.  Without adjustment for the strengthening
   U.S. dollar, Life Science and Clinical Diagnostics sales were
   4.8% and 4.3% lower, respectively, than reported above when
   compared to the prior period.  Sales in the Analytical
   Instruments segment declined as the Company sold its
   semiconductor instrument product line on August 1, 2000.  The
   divested sales from this product line were approximately $12.7
   million for the second quarter of 2000.

   Consolidated gross margins were 56.2% for the second quarter of
   2001 compared to 53.3% for the second quarter of 2000 and 52.7%
   for all of 2000.  The increased sales of products with higher
   gross margins, coupled with the benefit of increased volume on
   fixed factory costs, improved the overall Life Science gross
   margin.  Clinical Diagnostics margins improved due to the
   cessation of a distributor agreement, a large periodic customer
   order that shipped in June 2001 versus August 2000, an end to a
   "brand name" royalty, and improved overhead absorption at
   facilities shared with Life Science production.

   Selling, general and administrative expense (SG&A) decreased to
   33.4% of sales in the second quarter of 2001 from 34.2% of sales
   the second quarter of 2000.  To support increased sales, Life
   Science has invested in additional sales and sales support
   professionals, although at a rate of one-third of that of sales
   growth.  Clinical Diagnostics experienced a 2.9% increase in
   total SG&A expenditures.  The long-term goal for management
   remains a consistent gradual reduction in SG&A spending as a
   percent of sales.

   Product research and development expense decreased slightly to
   9.1% as a percentage of sales from 9.3% for the second quarter of
   2000.

   Corporate Results - Non-Operating Items

   Interest expense decreased from the prior year reflecting a
   reduction of debt and lower interest rates on variable rate debt.
   Net other income and expense in the second quarter of 2001
   declined principally from lower spending for non-operating legal
   costs and less investment income.  Net other income and expense
   in both years includes goodwill amortization of equal amounts.

   The Company's effective tax rate remains at 37.0% for the second
   quarter of 2001 compared to 32.0% in the second quarter of 2000.
   The increased rate reflects the limitation on the deductibility
   of goodwill amortization associated with the acquisition of
   Pasteur Sanofi Diagnostics (PSD), reduced utilization of loss
   carryforwards and a change in the geographical source of taxable
   income.


                                   9

   <page>

                    Six Months Ended June 30, 2001
               Compared to Six Months Ended June 30, 2000

   Corporate Results - Sales, Margins and Expenses

   Net sales (sales) for the first half of 2001 were $398.0 million
   compared to $372.3 million in the first half of 2000, an increase
   of 6.9%.  Adjusting for currency and divestitures, sales growth
   from new and existing products was 23.9%.  Sales increased 43.6%
   in Life Science on a constant currency basis.  Clinical
   Diagnostics sales growth adjusted for a product line divestiture
   on a constant currency basis, was 10.6%.  The growth in Life
   Science is attributed to strong demand for the Company's
   proteomic and genomic products.  Sales of the BSE test were
   significant as the product had negligible sales in the prior
   year.  The growth in Clinical Diagnostics was from products for
   quality controls, blood virus, autoimmune testing and diabetes
   monitoring.  Foreign sales for the first half of 2001 were
   adversely affected by the strengthening of the U.S. dollar versus
   the prior period.  Actual growth was approximately 4.7% less for
   both Life Science and Clinical Diagnostics than on the constant
   currency basis. Sales in the Analytical Instruments segment
   declined as the Company sold its semiconductor instrument product
   line effective August 1, 2000.

   Consolidated gross margins were 55.5% for the first half of 2001
   compared to 53.3% for the first half of 2000 and 52.7% for all of
   2000.  The increased sales of products with higher gross margins,
   coupled with the benefit of increased volume on fixed factory
   costs, improved the overall Life Science gross margin.  Clinical
   Diagnostics margins improved due to the cessation of a
   distributor agreement which had very low margins, reduced royalty
   expense, improved manufacturing overhead absorption and
   adjustments made in the prior year to have the acquired
   manufacturing sites comply with the Company's obsolescence and
   excess inventory policies.

   Selling, general and administrative expense (SG&A) decreased to
   32.1% of sales in the first half of 2001 from 34.0% of sales in
   the first half of 2000.  SG&A for Life Science increased 13.3% as
   sales grew at a rate three times faster.  Clinical Diagnostics
   experienced a small decrease in SG&A expenditures.  The long-term
   goal for management remains a consistent gradual reduction in
   SG&A spending as a percent of sales.

   Product research and development expense decreased slightly to
   9.1% as a percentage of sales from 9.5% for the first half of
   2000.

   Corporate Results - Non-Operating Items

   Interest expense decreased from the prior year reflecting a
   reduction of debt, reduced borrowing rates of variable rate debt
   and the absence of a $1.0 million fee on a bridge loan in 2000.
   Net other income and expense in the first half of 2001 includes


                                   10

   <page>



   $6.5 million of non-cash pre-tax expense relating to the impact
   of transactions in negotiation to transfer ownership in the
   Company spectroscopy instrument business and a change in the
   Company's valuation of an investment based on discussions with
   the investee's management concerning its future capital
   structure.  Foreign exchange losses increased compared to the
   prior period while non-operating litigation declined.  Net other
   income and expense in the first quarter of 2000 includes a $3.0
   million non-recurring payment to settle a dispute arising under
   the terms of an engagement letter between the Company and an
   investment bank.  Net other income and expense in both years
   includes goodwill amortization of approximately equal amounts.

   The Company's effective tax rate rose to 37.0% for the first half
   of 2001 compared to 32.0% in the first half of 2000.  The
   increased rate reflects the limitation on the deductibility of
   goodwill amortization associated with the acquisition of PSD, the
   utilization of loss carryforwards and a change in the
   geographical source of taxable income.

   Financial Condition

   The Company, as of June 30, 2001, had available approximately
   $100 million, or 100% of its principal revolving credit agreement
   and $34 million under various foreign lines of credit.  Cash and
   cash equivalents available were $26.1 million.

   At June 30, 2001, consolidated accounts receivable increased by
   $4.5 million from December 31, 2001.  The increase was due to
   significantly higher sales volume being offset by the declining
   value of receivables denominated in European and Japanese
   currencies as well as sales increases in the U.S. and Europe
   which have shorter payment terms than the developing regions of
   Asia and Latin America.

   At June 30, 2001, consolidated net inventories increased by $9.8
   million from December 31, 2000. Life Science increased inventory
   levels to meet customer demands for its consumable and apparatus
   products, build-up for new product launches, and increase safety
   stock during the transition of some significant suppliers.
   Clinical Diagnostic inventory levels remained unchanged as
   inventory increases for the quality control product lines were
   offset by other product lines.  Inventory for the Clinical
   Diagnostics quality controls business is characterized by long
   lead times and large infrequent batch production which is
   necessary to meet customers requirements.  Bio-Rad management
   regularly reviews inventory valuation for excess, obsolete and
   slow-moving products.

   Net capital expenditures totaled $19.7 million for the first six
   months of 2001 compared to $17.1 million for the same period of
   2000.  Capital expenditures for the period include reagent rental
   equipment placed with Clinical Diagnostic customers who then commit
   to purchase the Company's diagnostic reagents for use.  Other
   expenditures represent the Company's investment in business systems


                                    11

   <page>





   to standardize distribution software, data communication, production
   equipment and improvements to production facilities.  The Company
   acquired approximately 50,000 square feet of general office space in
   the Hercules business park near its Corporate headquarters.  Funds
   for the purchase came from the sale of the Company's property in
   Cambridge, Massachusetts.  The proceeds were in escrow pending the
   completion of a "like kind" exchange.

   The Company still believes that continued growth and the desire to
   fully comply with FDA standards and good manufacturing practices
   will cause it to require additional space in Northern California for
   manufacturing, laboratory and general office use.  Management is
   currently reviewing its space requirements and financing
   alternatives that could result in increased capital expenditures
   later in 2001 and beyond.

   On July 27, 2001, the Company purchased for cash all of the
   outstanding shares of Helix Diagnostics, Inc., an autoimmune
   diagnostics test manufacturer based near San Francisco.  The amount
   paid was not material.  The purchase will add further competency in
   manufacturing autoimmune products to our existing Clinical
   Diagnostics segment.

   The Company has determined that the sale or disposal of certain
   remaining portions of the Analytical Instruments segment is
   appropriate.  The Company recorded a $4.5 million non-cash charge in
   the first quarter of 2001 reflecting the potential impact of a non-
   binding letter of intent to sell the spectroscopy instrument
   business to a new owner.  The parties continued to work together
   during the second quarter on a definitive agreement and the buyer's
   financing requirements.  We cannot guarantee, however, that the
   Company will be successful in completing this transaction. Should it
   not happen, the Company will immediately pursue other alternatives.

   Euro - A New European Currency

   On January 1, 1999, certain member countries of the European Union
   began to fix the conversion rates between their national currencies
   and a common currency, the "Euro."   Over the period January 1, 1999
   through January 1, 2002 participating countries will gradually
   transition from their national currencies to the Euro.

   This transition will have business implications including the need
   to adjust internal systems to accommodate the Euro and cross-border
   price transparency.  A group of Corporate and European managers have
   been assigned the task of preparing and accommodating the changes
   required to continue to do business in the European Union.  The
   Company has not experienced to date nor does it expect that these
   changes will have a material impact on operations, financial
   position or liquidity.  There will be increased competitive
   pressures as a result of the change, and marketing strategies will
   need to be continuously evaluated until the transition is complete.



                                    12




   <page>


   As a result of competitive forces and government regulations, the
   Company cannot guarantee that all problems will be foreseen and
   remediated, and that no material disruption will occur.

   New Financial Accounting Standards

   In July 2001, the Financial Accounting Standards Board issued
   Statements of Financial Accounting Standards (SFAS) No. 141,
   "Business Combinations" and No. 142, "Goodwill and Other
   Intangible Assets".  SFAS 141 is effective for any business
   combination initiated after June 30, 2001 and also includes the
   criteria for the recognition of intangible assets separately from
   goodwill.  SFAS 142 will be effective for fiscal years beginning
   after December 15, 2001 and will require that goodwill not be
   amortized, but rather be subject to an impairment test at least
   annually.  The Company is currently evaluating the effect that
   adoption of the provisions of SFAS 142 will have on its results
   of operations and financial position.

   Item 3.   Quantitative and Qualitative Disclosures
             About Market Risk

   During the six months ended June 30, 2001, there have been no
   material changes from the disclosures about market risk provided
   in the Company's Annual Report on Form 10-K for the year ended
   December 31, 2000.

   PART II.  OTHER INFORMATION

   Item 6.  Exhibits and Reports on Form 8-K.

   (a)  Exhibits

        None

   (b)  Reports on Form 8-K

   There were no reports on Form 8-K for the quarter ended
   June 30, 2001.










                                   13

   <page>










                              SIGNATURES


  Pursuant to the  requirements of the  Securities Exchange Act  of
  1934, the registrant  has duly caused this report to be signed on
  its behalf by the undersigned thereto duly authorized.

                                BIO-RAD LABORATORIES, INC.
                                      (Registrant)



  Date:  August 13, 2001   /s/ T. C. Chesterman
                           -------------------------------------
                           T. C. Chesterman, Vice President,
                                Chief Financial Officer



  Date:  August 13, 2001   /s/ James R. Stark
                           -------------------------------------
                           James R. Stark, Corporate Controller





















</TEXT>
</DOCUMENT>
